Scalper1 News
Canadian drugmaker and serial acquirer Valeant Pharmaceuticals International (VRX) entered into a tentative agreement to buy the assets of bankrupt biotech Dendreon late Thursday, including Dendreon’s controversial “cancer vaccine” Provenge. Valeant and Dendreon entered into a “stalking horse” asset purchase agreement, under which Valeant is the preferred bidder in Dendreon’s asset sale. Valeant agreed to pay $296 million for the assets and is Scalper1 News
Scalper1 News